2. Signaling Pathways
  3. Neuronal Signaling
  4. Tau Protein

Tau Protein

Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162860
    FO-4-15
    		Inhibitor
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage.
    FO-4-15
  • HY-177626
    Diranersen
    		Inhibitor
    Diranersen, an antisense oligonucleotide, is a tau protein synthesis reducer. It is used for the study of Alzheimer's disease.
    Diranersen
  • HY-174398
    GSK-3β/HDAC-IN-2
    		Inhibitor
    GSK-3β/HDAC-IN-2 is a potent inhibitor of GSK-3β (IC50 = 0.04 μM), HDAC2 (IC50 = 1.05 μM, Ki = 0.070 μM) and HDAC6 (IC50 = 1.52 μM, Ki = 0.017 μM). GSK-3β/HDAC-IN-2 inhibits HDAC2 and HDAC6 activities and blocks tau hyperphosphorylation. GSK-3β/HDAC-IN-2 exerts neuroprotective effects and shows no significant toxicity. GSK-3β/HDAC-IN-2 can be used in the research of Alzheimer's disease.
    GSK-3β/HDAC-IN-2
  • HY-162020
    SB1617
    		Inhibitor
    SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity.
    SB1617
  • HY-168857
    GSK-3β inhibitor 24
    		Inhibitor
    GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects.
    GSK-3β inhibitor 24
  • HY-147321
    3'-DMTr-dG(iBu)
    3'-DMTr-dG(iBu) is a nucleoside for the synthesis of nucleic acid, such as antiviral agents used in the research of viral infection (HBV, HDV), and oligonucleotides against Alzheimer’s disease and other tauopathies.
    3'-DMTr-dG(iBu)
  • HY-161448
    Tau-aggregation-IN-3
    		Inhibitor
    Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC50=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research.
    Tau-aggregation-IN-3
  • HY-149233
    hAChE-IN-1
    		Inhibitor
    hAChE-IN-1 (Compound 24) is a potent hAChE inhibitor with an IC50 of 1.09 μM. hAChE-IN-1 inhibits tau-oligomerization with an EC50 of 2.71 μM in cellular tau FRET assay.
    hAChE-IN-1
  • HY-164341
    TAU-IN-2
    		Inhibitor
    TAU-IN-2 (Example 25) is a TAU inhibitor with an EC50 value of 7.7 nM. TAU-IN-2 can be used in the study of neurodegenerative diseases.
    TAU-IN-2
  • HY-177626A
    Diranersen sodium
    		Inhibitor
    Diranersen sodium, an antisense oligonucleotide, is a tau protein synthesis reducer. It is used for the study of Alzheimer's disease.
    Diranersen sodium
  • HY-120744
    LDN-193665
    		Inhibitor
    LDN-193665 is a Tau kinase inhibitor with tauopathy-modifying activity. LDN-193665 inhibits Tau phosphorylation, improves tauopathy in animal models, reduces Sarkosyl-insoluble Tau, and restores memory. It may be necessary to simultaneously target multiple kinases to effectively inhibit tauopathies.
    LDN-193665
  • HY-P991704
    Moponetug
    		Inhibitor
    Moponetug is a humanized IgG1κ antibody targeting MAPT. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
    Moponetug
  • HY-172542
    TTBK1/2-IN-1
    		Inhibitor
    TTBK1/2-IN-1 (compound 3) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 816 nM and 384 nM, respectively.
    TTBK1/2-IN-1
  • HY-175841
    Tau Protein Phosphorylation-IN-1
    		Inhibitor
    Tau Protein Phosphorylation-IN-1 is a tau protein phosphorylation inhibitor that potently protects PC12 cells against Aβ25–35-induced cytotoxicity (EC50 = 1.93 μM), and can penetrate the blood-brain barrier (BBB).Tau Protein Phosphorylation-IN-1 reverses the hyperphosphorylation of tau, significantly inhibits the expression of certain immune-related cytotoxic factors, suppresses the MAPK and NF-κB signaling pathways, and significantly inhibits the expression of RAGE and the apoptosis factors Bax/Bcl-2, both in vitro and in vivo. Tau Protein Phosphorylation-IN-1 relieves nerve damage, and improves learning and memory in an Alzheimer’s disease (AD) mouse model. Tau Protein Phosphorylation-IN-1 can be used for AD research.
    Tau Protein Phosphorylation-IN-1
  • HY-13486
    TAU-IN-1
    		Inhibitor
    TAU-IN-1 (compound 051) is a TAU protein inhibitor with an EC50 value of 325 nM. TAU-IN-1 can be used in the study of neurodegenerative diseases.
    TAU-IN-1
  • HY-153427
    Tau protein aggregation-IN-1
    		Inhibitor
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies.
    Tau protein aggregation-IN-1
  • HY-175840
    TAU-IN-5
    		Inhibitor
    TAU-IN-5 (compound 13) is a TAU protein inhibitor with an EC50 of 0.81 μM. TAU-IN-5 inhibits the formation of tau (2N4R isoform) oligomers and reduces the formation of tau dimers. TAU-IN-5 can be used in the study of Alzheimer's disease (AD) and Parkinson's disease (PD).
    TAU-IN-5
  • HY-P4923
    Tau Peptide (1-16) (human)
    Tau Peptide (1-16) (human) is aTau fragment.
    Tau Peptide (1-16) (human)
  • HY-160481
    MG-1102
    		Inhibitor
    MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC50s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a Kd of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD).
    MG-1102
  • HY-P10861
    RI-AG03
    		Inhibitor
    RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease.
    RI-AG03
Cat. No. Product Name / Synonyms Application Reactivity